Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.56 USD
-0.04 (-0.71%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $5.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.56 USD
-0.04 (-0.71%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $5.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Zacks News
Spero's (SPRO) IND Accepted by FDA for Pulmonary Disease Drug
by Zacks Equity Research
The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.
Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes
by Zacks Equity Research
Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.
Alnylam's Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study
by Zacks Equity Research
Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.
5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. The company's efforts to develop its pipeline are impressive.
Pluristem Completes Enrollment in Phase I Hematology Study
by Zacks Equity Research
Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.
Unity Shares Slump 66% As Lead Arthritis Drug Fails in Study
by Zacks Equity Research
Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.
Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies
by Zacks Equity Research
Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.
AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.
Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected
by Zacks Equity Research
AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales
by Zacks Equity Research
Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.
What Makes Alimera Sciences (ALIM) a New Strong Buy Stock
by Zacks Equity Research
Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks For August 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.
New Strong Buy Stocks For June 25th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
EyePoint Pharmaceuticals (EYPT) Surges: Stock Moves 7.4% Higher
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
New Strong Buy Stocks for June 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 121.62% and 19.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Alimera Sciences has been struggling lately, but the selling pressure may be coming to an end soon.